CCSG developmental funds leveraged additional institutional support and provided an exceptionally strong return on investment. The $350,000 CCSG support of the New Investigator Award Program was supplemented by $80,000 of institutional/philanthropic funds, allocated to eight new faculty recruits, and generated a total of $9 million (total costs) in grant support. The $1.2 million CCSG support of the Pilot Project Program was supplemented by $1.5 million of institutional/philanthropic funds, generating $17.8 million (total costs) in grant support. The grand total of $26.8 million return on investment (ROI) includes over $26.6 million in peer reviewed grant support, and represents a 17.5-fold ROI of CCSG funds invested for New Investigator Awards and Pilot Projects. CCSG developmental funds further enabled shared resource evolution. The Metabolomics shared resource has matured to an established shared resource that offers unique technical expertise and ease-of-access to state-of-the-art instrumentation and current protocols that are not available in most individual investigator laboratories; this resource continues to fuel collaborative research with Princeton University and over a recent twelve-month period, served 19 investigators (17 of whom are CINJ members) across three CINJ programs. Given the continued substantial growth of the CINJ research enterprise, and the successful use of developmental funds in the current project period, we request $425,000 per year to be used in three categories: 1) recruitment of investigators in areas of strategic priority for CINJ (New Investigator Award program), 2) development of new shared resources in Immune Monitoring (responding to the Director?s initiative in Immune Oncology) and Small Molecule Screening (critical to all Basic programs and specifically responsive to a 2011 critique of the Cancer Pharmacology Program), and 3) pilot awards (Pilot Project program) to promote novel, collaborative research aligned with strategic priorities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA072720-20
Application #
9632909
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-03-01
Budget End
2020-02-29
Support Year
20
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Zhu, Sining; Jin, Juan; Gokhale, Samantha et al. (2018) Genetic Alterations of TRAF Proteins in Human Cancers. Front Immunol 9:2111
Perekatt, Ansu O; Shah, Pooja P; Cheung, Shannon et al. (2018) SMAD4 Suppresses WNT-Driven Dedifferentiation and Oncogenesis in the Differentiated Gut Epithelium. Cancer Res 78:4878-4890
Llanos, Adana A M; Tsui, Jennifer; Rotter, David et al. (2018) Factors associated with high-risk human papillomavirus test utilization and infection: a population-based study of uninsured and underinsured women. BMC Womens Health 18:162
Hadigol, Mohammad; Khiabanian, Hossein (2018) MERIT reveals the impact of genomic context on sequencing error rate in ultra-deep applications. BMC Bioinformatics 19:219
Severson, Eric A; Riedlinger, Gregory M; Connelly, Caitlin F et al. (2018) Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood 131:2501-2505
Shih, Weichung Joe; Lin, Yong (2018) Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers. Stat Med 37:687-709
Ding, Qiang; Gaska, Jenna M; Douam, Florian et al. (2018) Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease. Proc Natl Acad Sci U S A 115:E6310-E6318
Winer, Benjamin Y; Shirvani-Dastgerdi, Elham; Bram, Yaron et al. (2018) Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med 10:
Modi, Parth K; Wang, Ye; Kirk, Peter S et al. (2018) The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology 117:50-56
Dai, Zhuqing; Feng, Simin; Liu, Anna et al. (2018) Anti-inflammatory effects of newly synthesized ?-galacto-oligosaccharides on dextran sulfate sodium-induced colitis in C57BL/6J mice. Food Res Int 109:350-357

Showing the most recent 10 out of 775 publications